B. Riley Has Bullish Outlook for Harrow FY2025 Earnings

Key Points

• B. Riley has raised its FY2025 earnings per share estimate for Harrow, Inc. from $0.56 to $0.88, while also forecasting FY2026 earnings at $2.78 EPS.
• Harrow's recent earnings report showed a significant beat with $0.24 EPS compared to analysts' expectations of $0.01, despite a negative net margin of 4.49%.
• Analysts are optimistic about Harrow, with several firms issuing "buy" ratings and target price increases; the current average price target is $64.67.

Harrow, Inc. (NASDAQ:HROW - Free Report) - B. Riley increased their FY2025 EPS estimates for Harrow in a research note issued on Thursday, August 21st. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of $0.88 for the year, up from their prior estimate of $0.56. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow's FY2026 earnings at $2.78 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. The firm had revenue of $63.74 million during the quarter, compared to analyst estimates of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

Several other research analysts have also commented on the stock. BTIG Research lifted their price objective on shares of Harrow from $62.00 to $63.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. Zacks Research raised shares of Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Cantor Fitzgerald started coverage on shares of Harrow in a research note on Friday, July 11th. They set an "overweight" rating and a $76.00 target price for the company. HC Wainwright boosted their target price on shares of Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. Finally, William Blair started coverage on shares of Harrow in a research note on Tuesday, June 10th. They set an "outperform" rating for the company. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. According to data from MarketBeat, Harrow has an average rating of "Buy" and an average price target of $64.67.

Harrow Trading Up 2.5%

HROW stock opened at $39.12 on Monday. The firm has a fifty day moving average price of $33.93 and a 200 day moving average price of $29.14. Harrow has a fifty-two week low of $20.85 and a fifty-two week high of $59.23. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. The firm has a market cap of $1.45 billion, a PE ratio of -156.48 and a beta of 0.41.

Hedge Funds Weigh In On Harrow

Several hedge funds have recently modified their holdings of HROW. Barclays PLC increased its holdings in shares of Harrow by 15.1% during the fourth quarter. Barclays PLC now owns 60,550 shares of the company's stock valued at $2,032,000 after acquiring an additional 7,957 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of Harrow by 5.7% during the fourth quarter. MetLife Investment Management LLC now owns 18,908 shares of the company's stock valued at $634,000 after acquiring an additional 1,026 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after acquiring an additional 1,462 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Harrow by 8.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,076 shares of the company's stock valued at $640,000 after acquiring an additional 1,428 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in Harrow in the fourth quarter valued at approximately $78,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.